Showing 2623 results
- https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal1-umsatzsteigerungen-kwk-deutlich-hohere-margen-kwk-und-beachtliche-innovationen-jetzt-mit-einem-starker-fokussierten-portfolioDie fortzuführenden Geschäftsbereiche[1] steigern im ersten Quartal den Umsatz, das operative Kernergebnis[2] und den Kerngewinn pro Aktie (kWk[2]) Der Nettoumsatz beläuft sich auf USD 11,9…
- https://www.novartis.com/news/media-releases/novartis-celebrates-19th-annual-community-partnership-day-more-27000-associates-volunteering-their-local-communitiesMore than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities Community Partnership Day symbolizes the company'…
- https://www.novartis.com/news/media-releases/data-aan-showed-gilenya-high-efficacy-achieving-no-evidence-disease-activity-previously-treated-highly-active-ms-patientsNew FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo NEDA4 is based on four…
- https://www.novartis.com/news/media-releases/sandoz-receives-fda-approval-glatopatm-first-generic-competitor-ms-therapy-copaxone-20mgGlatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full…
- https://www.novartis.com/news/media-releases/alcon-receives-fda-approval-new-multifocal-intraocular-lens-treat-cataract-patients-united-statesUS Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the …
- https://www.novartis.com/news/media-releases/sandoz-receives-fda-approval-tyruko-natalizumab-sztn-first-and-only-fda-approved-biosimilar-relapsing-forms-multiple-sclerosisBiosimilar Tyruko® approved for all indications of reference medicine, with same dosing and administration schedule Sandoz continues to expand access to much-needed medications for patients…
- https://www.novartis.com/news/media-library/cardiovascular-disease-orion-8-media-summary
- https://www.novartis.com/news/media-releases/data-lancet-show-novartis-drug-arzerra-plus-chlorambucil-improved-median-progression-free-survival-71-cll-patientsSignificant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic…
- https://www.novartis.com/news/media-releases/gilenya-data-aan-highlight-novartis-leadership-innovation-new-ms-assessment-methods-benefit-patients-and-physiciansNew analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding…
- https://www.novartis.com/news/media-releases/novartis-announces-fda-approval-jadenutm-simplify-treatment-administration-patients-chronic-iron-overloadJadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page